Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 99.43B |
| Revenue (ttm) | 10.27B |
| Net Income (ttm) | -914.93M |
| Shares Out | n/a |
| EPS (ttm) | -3.55 |
| PE Ratio | n/a |
| Forward PE | 23.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 81 |
| Open | 387.20 |
| Previous Close | 382.35 |
| Day's Range | 387.20 - 388.90 |
| 52-Week Range | 362.70 - 489.20 |
| Beta | 0.46 |
| RSI | 39.40 |
| Earnings Date | Aug 4, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORW...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ETCompany...
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 10 years by 2.68% on an annualized basis producing an average annual return of 13.76%. Currently, Vertex Pharmaceutical...
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It
ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potentia...
Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in p...
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with ...
Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceutica...
Vertex Pharma announces new share buybacks worth up to $4B
Vertex to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss
Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 2025 results. Read more here.
SA analyst upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB
Explore recent stock upgrades by Seeking Alpha: TSLA, MSFT, AMD & more! Discover insights and investment strategies for outperforming the market.
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain manage...
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S. ... Full story available on Benzinga.com
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Heres Why.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following ...
Vertex Pharmaceuticals Stock Sinks as Costs Soar
Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.